Article
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Hepatology (Baltimore, Md.) - 1 Oct 2015
Kumada Hiromitsu, Chayama Kazuaki, Rodrigues Lino, Suzuki Fumitaka, Ikeda Kenji, Toyoda Hidenori, Sato Ken, Karino Yoshiyasu, Matsuzaki Yasushi, Kioka Kiyohide, Setze Carolyn, Pilot-Matias Tami, Patwardhan Meenal, Vilchez Regis A, Burroughs Margaret, Redman Rebecca
Abstract excerpt
UNLABELLED: GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b-infected patients. It consists of a double-blind, placebo-controlled substudy of patients without cirrhosis and an open-label substudy of patients with compensated cirrhosis. Patients without...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.